Decision Tables for Calibration-Free Odds Design in Phase I Clinical Trials [0.03%]
基于校准的免校验概率设计的一期临床试验决策表
Ninghao Zhang,Guosheng Yin
Ninghao Zhang
In clinical trials, the initial step typically involves assessing a new drug's toxicity profile, aiming to identify a tolerable dose level for subsequent studies. In phase I trials, the primary objective is to determine the maximum tolerate...
Immune Checkpoint Inhibitors for Mismatch Repair-Deficient Gastroesophageal Adenocarcinoma: Outcomes and Feasibility of Nonoperative Management at Mayo Clinic [0.03%]
胃食管腺癌错配修复缺陷型免疫检查点抑制剂治疗的结局及 mayo clinic 非手术治疗可行性的研究
Oudai Sahwan,Fares Jamal,Rish Pai et al.
Oudai Sahwan et al.
Purpose: Neoadjuvant immune checkpoint inhibitors (nICIs) have demonstrated high response rates in deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastroesophageal adenocarcinoma (GEA). The NEONIPIG...
Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms [0.03%]
胃肠胰神经内分泌肿瘤中DLK表达及功能显像
Rohit Thummalapalli,Salomon Tendler,Joanne F Chou et al.
Rohit Thummalapalli et al.
Purpose: Delta-like ligand 3 (DLL3) is an emerging target across neuroendocrine cancers, but remains underexplored in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs), including poorly differentiated gastroenter...
Actionable Genomic Alterations in Large Cell Neuroendocrine Carcinoma: A European Case Series of Patients Treated With a Small Molecule Inhibitor [0.03%]
欧洲小分子抑制剂治疗大细胞神经内分泌癌病例系列：具有可操作基因组改变的大细胞神经内分泌癌
Frank W J Heijboer,Marta Brambilla,Mario Occhipinti et al.
Frank W J Heijboer et al.
Purpose: Actionable genomic alterations (AGA) are rare in large cell neuroendocrine carcinoma (LCNEC), and outcomes with small molecule inhibitors (SMI) are not well studied. We evaluated SMI response in LCNEC with AGAs, ...
Multicenter Study
JCO precision oncology. 2025 Nov:9:e2500293. DOI:10.1200/PO-25-00293 2025
Mixed Molecular Subtypes Coexist in Estrogen Receptor Heterogeneous Primary Breast Cancers [0.03%]
雌激素受体异质性原发乳腺癌中混合分子亚型共存
Julia Foldi,Kaitlyn Xiong,Matthew Liu et al.
Julia Foldi et al.
Purpose: We performed spatial transcriptomics of estrogen receptor (ER)-negative, ER-low, and ER-high tumor regions of breast cancers that were intermediate (10%-60%) ER-positive by immunohistochemistry to better understa...
Evaluation of Raw Cell-Free DNA Sequences for Gastric Cancer Detection [0.03%]
基于胃癌早筛需求对cfDNA原始测序序列的评估研究
Ye Tian,Yichen Yang,Jilei Liu et al.
Ye Tian et al.
Purpose: Gastric cancer (GC) is a significant global health challenge, often diagnosed late, limiting treatment success. Early detection through biomarkers is critical for better outcomes. This study developed a noninvasi...
Nirmish Singla
Nirmish Singla
Single-Cell Immune Signature and Response to Neoadjuvant Chemotherapy in BRCA1/2-Mutated Breast Cancer [0.03%]
BRCA1/2突变型乳腺癌的单细胞免疫特征及新辅助化疗反应
Li Hu,Linxi Chen,Yaxin Zhang et al.
Li Hu et al.
Purpose: The atlas of immune microenvironment at single-cell level in BRCA1/2-mutated breast cancer is largely unknown and whether an immune signature on the basis of single-cell atlas is associated with response to neoad...
Liposarcoma and Leiomyosarcoma as the First Manifestation of Familial Retinoblastoma: Implications for Genetic Testing and Carrier Surveillance [0.03%]
家族性视网膜母细胞瘤患者中首次出现脂肪肉瘤和平滑肌肉瘤：基因检测和携带者监测的启示
Claire Johns,Molly McGuinness,Kerry Kingham et al.
Claire Johns et al.
Genomic Landscape and Outcomes of Renal Cell Carcinoma With Metastases to the Pancreas [0.03%]
肾癌胰腺转移的基因组谱系和预后研究
Michael J Glover,Arya Ashok,Osama Khan et al.
Michael J Glover et al.
Purpose: Renal cell carcinoma (RCC) that metastasizes to the pancreas (RCC-PM) is a rare but known phenomenon. These patients have been described to have indolent disease and longer overall survival than patients with met...